Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 264

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 264
---
 many factors, including but not limited to the following:

•our ability to continue to generate revenues from sales of commercial products and potential future products;

•the timing and costs associated with our expansion efforts;

•the timing and costs associated with repurchases of our common stock under our $500.0 million share repurchase program, approved by our Board of Directors in November 2024 and effective for 18 months;

•the timing and costs of building out our manufacturing capabilities;

•the timing of payments related to our future inventory commitments and manufacturing obligations;

-79-

•the timing and costs associated with our existing lease obligations and new obligations expected to be entered into in future years;

•the timing and costs associated with our clinical trials and pre-clinical trials;

•the attainment of milestones and our obligations to make milestone payments to Arrowhead, Myonexus's selling shareholders, BioMarin, Nationwide, UWA and other institutions; 

•obligations to holders of our 1.25% convertible senior notes due on September 15, 2027 (“2027 Notes”); and

•the costs of filing, prosecuting, defending and enforcing patent claims and our other intellectual property rights.

We cannot provide assurances that financing will be available when and as needed or that, if available, the financings will be on favorable or acceptable terms. If we are unable to obtain additional financing when and if we require, this would have a material adverse effect on our business and the results of operations. To the extent we issue additional equity securities, our existing stockholders could experience substantial dilution. We believe that existing cash and cash equivalents, along with future cash generated from operations will be sufficient to meet the capital requirements of our operations for the next 12 months and foreseeable future.

We have entered into long-term contractual arrangements from time to time for our facilities, the provision of goods and services, and issuance of debt securities, among others. Additional information regarding our obligations under debt, lease, and manufacturing arrangements is provided in Note 13, Indebtedness, Note 19, Leases, Note 22, Commitments and Contingencies and Note 23, Subsequent event, respectively, to the consolidated financial statements. The following table summarizes our total obligations under debt, lease, and manufacturing arrangements:

    As of December 31, 2024

    Due in less than one year

    Due in greater than one year

    Total

    (in thousands)

    Debt obligations (1)
     
    $